How India Exports Cefuroxime to the World

In the United States, cefuroxime is approved through Abbreviated New Drug Applications (ANDAs), allowing generic manufacturers to market the drug upon demonstrating bioequivalence to the reference listed drug. The FDA's Orange Book lists multiple approved ANDAs for cefuroxime, indicating a competitive market with several generic options available. Notably, there have been no recent import alerts or significant regulatory actions affecting cefuroxime imports from India, suggesting compliance with FDA standards. Given that 17.0% of India's cefuroxime exports are destined for the U.S., it is imperative for Indian exporters to maintain stringent adherence to FDA regulations to ensure uninterrupted market access.

In the European Union, cefuroxime is subject to marketing authorization procedures overseen by the European Medicines Agency (EMA). A notable regulatory action occurred in April 2007 when the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended amendments to the Summary of Product Characteristics for cefuroxime axetil, particularly concerning its indication for uncomplicated gonorrhoea. This decision was based on concerns regarding the safety and efficacy of cefuroxime in treating this condition. The European Commission adopted this decision in August 2007. Additionally, in May 2012, the EMA completed a review of Zinacef (cefuroxime sodium), leading to harmonized prescribing information across EU member states. Compliance with EU Good Manufacturing Practice (GMP) standards is mandatory for Indian exporters to ensure product quality and safety.

Cefuroxime is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in treating bacterial infections. The drug is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality parameters globally. While specific WHO Prequalification listings for cefuroxime are not detailed, its inclusion in the Essential Medicines List highlights its critical role in public health.

In India, cefuroxime is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of the latest updates, cefuroxime is not listed under the Drugs (Prices Control) Order (DPCO), suggesting no ceiling price is currently imposed. For exports, the Central Drugs Standard Control Organization (CDSCO) mandates a No Objection Certificate (NOC) to ensure compliance with regulatory standards.

The primary patents for cefuroxime have expired, leading to a robust generic market with multiple manufacturers producing the drug. This competitive landscape has contributed to the widespread availability and affordability of cefuroxime globally.

In January 2023, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended updates to the product information for cefuroxime axetil, emphasizing the need for monitoring potential adverse reactions. This underscores the importance of ongoing pharmacovigilance for established antibiotics.

In April 2023, the EMA completed a periodic safety update report (PSUR) single assessment for cefuroxime sodium (except for intracameral use), resulting in variations to the marketing authorizations to enhance safety information. This reflects the continuous efforts to ensure the safe use of cefuroxime in the EU market.

In August 2023, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of cefuroxime, highlighting its ongoing relevance in global health.

In October 2023, the CDSCO issued a directive requiring all cefuroxime manufacturers to submit updated stability data, aiming to ensure product efficacy throughout its shelf life.

In December 2023, the NPPA conducted a review of antibiotic pricing, including cefuroxime, to assess the need for potential price controls, reflecting the authority's commitment to making essential medicines affordable.

These developments highlight the dynamic regulatory environment surrounding cefuroxime, emphasizing the need for manufacturers and exporters to stay informed and compliant with evolving standards.

India is a significant producer of Active Pharmaceutical Ingredients (APIs), including those for cefuroxime. However, the country heavily depends on China for Key Starting Materials (KSMs) essential in API synthesis. This reliance exposes the supply chain to risks associated with geopolitical tensions and trade restrictions. For instance, in 2025, the U.S. imposed tariffs of up to 100% on branded drugs imported from countries without domestic manufacturing facilities, directly impacting global supply chains and prompting major pharmaceutical companies to invest in U.S.-based production.

Such disruptions underscore the vulnerability of India's pharmaceutical supply chain due to its dependence on Chinese KSMs. Any interruption in this supply can lead to production delays and increased costs for cefuroxime manufacturers in India.

Our data indicates that the top five exporters of cefuroxime from India account for 53.6% of total exports, with SUN PHARMACEUTICAL INDUSTRIES LIMITED leading at 16.3%. This concentration suggests a moderate risk, as disruptions affecting these key players could significantly impact global supply.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of critical APIs and reduce dependency on imports. This initiative is expected to diversify the supplier base and enhance supply chain resilience.

Geopolitical events have notably disrupted global supply chains. The ongoing Iran war has severely disrupted global supply chains, primarily by halting oil tanker movement through the critical Strait of Hormuz. This choke point is essential for global commerce, affecting not only oil supply but also the distribution of pharmaceuticals from India.

Additionally, the U.S. has imposed tariffs of up to 100% on branded drugs imported from countries without domestic manufacturing facilities, directly impacting global supply chains and prompting major pharmaceutical companies to invest in U.S.-based production.

These disruptions have led to increased transportation costs and delays, affecting the timely delivery of pharmaceuticals, including cefuroxime.

• Diversify KSM Sources: Reduce dependency on Chinese KSMs by developing alternative sources, either domestically or from other countries.

• Strengthen Domestic Manufacturing: Leverage the PLI scheme to enhance local production capabilities for APIs and KSMs.

• Enhance Supplier Base: Encourage the growth of smaller manufacturers to reduce reliance on a few large exporters.

• Monitor Geopolitical Developments: Establish a dedicated team to track and assess geopolitical events that could impact supply chains.

• Develop Contingency Plans: Create robust strategies to address potential shipping disruptions, including alternative routes and logistics partners.

RISK_LEVEL: MEDIUM